Sartorius Stedim Shares Drop 3.5% Despite Upside Potential According to Jefferies
On Thursday morning, Sartorius Stedim Biotech fell by 3.49% to €169.95 amidst a significant downturn of the CAC 40, which is down by 1.64% during the session. The stock has intensified its downward trend over three months, accumulating a decline of 16.57%. However, two research firms had raised their price targets the day before.
Upward Price Target Revisions Despite Today's Decline
Despite the decline recorded this Thursday, Sartorius Stedim Biotech was subject to two upward revisions of price targets published on Wednesday, March 18. Oddo BHF raised its target from €248 to €253 while maintaining an 'outperform' rating. Jefferies, on the other hand, increased its target from €256 to €262, maintaining a 'buy' rating. At the current price of €169.95, these targets suggest a revaluation potential, but a considerable gap compared to the market valuation. The upcoming financial calendar could provide new elements for assessment. The general assembly is set to decide on the dividend payment on March 24, with payment scheduled for April 2. The first quarter 2026 results, expected on April 23, will be an important milestone to assess the operational trajectory of the group.
Technical Perspective Shows Selling Pressure
From a technical standpoint, the share price of Sartorius Stedim Biotech is significantly below its 50-day and 200-day moving averages, which stand at €186.57 and €190.75 respectively. This deviation, around 9 to 12%, indicates a selling pressure that has been in place for several weeks, confirmed by a year-on-year decline of 15.62%. The stock is approaching a support threshold identified at €160.15, a technical level that could play a role in the coming sessions if the decline continues. The RSI, at 45, remains in a neutral zone, without any immediate oversold signal, indicating that the downward movement has not yet reached an excess level likely to trigger a mechanical rebound. The market context is not helping: the SBF 120 is down by 1.65% in session, while other European tech stocks are also facing sell-offs, like ASML Holding (-2.70%) and Prosus (-3.45%). The monthly volatility of the stock, measured at 13.64%, remains moderate, but its negative beta of -0.13 suggests a historically decoupled behavior from major indices, which does not prevent the stock from participating in the general downward movement this morning.
